1Scagliotti GV,Selvaggi G,Novello S,et al. The biology of epidermal growth factor receptor in lung cancer.Clin Cancer Res,2004,10(12pt2):4227s-4232s.
2Riely GJ,Politi KA,Miller VA,et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer.Clin Cancer Res,2006,12 (24):7232-7241.
3Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib.N Engl J Med,2004,350(21):2129-2139.
4Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science,2004,304(5676):1497-1500.
5Riely GJ,Pao W,Pham D,et al.Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Clin Cancer Res,2006,12(3ptl):839-844.
6Shigematsu H,Lin L,Takahashi T,et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.J Natl Cancer Inst,2005,97(5):339-346.
7Kosaka T,Yatabe Y,Endoh H,et al.Mutations of the epidermal growth factor receptor gene in lung cancer:biological and clinical implications.Cancer Res,2004,64 (24):8919 -8923.
8Hsieh RK, Lim KH, Kuo HT, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.Chest,2005,128 (1):317 -321.
9Miller VA,Kris MG,Shah N,et al.Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.J Clin Oncol,2004,22(6):1103-1109.
10Marchetti A,Martella C,Felicioni L,et al.EGFR mutations in non-small-cell lung cancer:analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.J Clin 0ncol,2005,23(4):857-865.
